Loading...

Avita Medical

DB:GCR
Snowflake Description

Excellent balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
GCR
DB
A$662M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Avita Medical Limited operates as a regenerative medicine company in the Asia Pacific, Europe, the Middle East, Africa, and the Americas. The last earnings update was 53 days ago. More info.


Add to Portfolio Compare Print
  • Avita Medical has significant price volatility in the past 3 months.
GCR Share Price and Events
7 Day Returns
-9.8%
DB:GCR
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
653.6%
DB:GCR
-10.2%
DE Biotechs
-6%
DE Market
GCR Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Avita Medical (GCR) -9.8% 17.2% 189% 653.6% 73% 224.6%
DE Biotechs -2.4% 3.2% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.6% 7.4% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • GCR outperformed the Biotechs industry which returned -10.2% over the past year.
  • GCR outperformed the Market in Germany which returned -6% over the past year.
Price Volatility
GCR
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Avita Medical undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Avita Medical. This is due to cash flow or dividend data being unavailable. The share price is €0.211.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Avita Medical's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Avita Medical's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:GCR PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in AUD A$-0.02
ASX:AVH Share Price ** ASX (2019-04-18) in AUD A$0.36
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Avita Medical.

DB:GCR PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:AVH Share Price ÷ EPS (both in AUD)

= 0.36 ÷ -0.02

-14.66x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Avita Medical is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Avita Medical is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Avita Medical's expected growth come at a high price?
Raw Data
DB:GCR PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -14.66x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
48.8%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Avita Medical, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Avita Medical's assets?
Raw Data
DB:GCR PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in AUD A$0.02
ASX:AVH Share Price * ASX (2019-04-18) in AUD A$0.36
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:GCR PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:AVH Share Price ÷ Book Value per Share (both in AUD)

= 0.36 ÷ 0.02

18.77x

* Primary Listing of Avita Medical.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Avita Medical is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Avita Medical's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Avita Medical has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Avita Medical expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
48.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Avita Medical expected to grow at an attractive rate?
  • Unable to compare Avita Medical's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Avita Medical's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Avita Medical's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:GCR Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:GCR Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 48.8%
DB:GCR Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 46.7%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:GCR Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:GCR Future Estimates Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-06-30 34 -8 -5 1
2020-06-30 33 -20 -14 2
2019-06-30 23 -17 -23 2
DB:GCR Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2018-12-31 3 -19 -25
2018-09-30 2 -18 -21
2018-06-30 2 -16 -17
2018-03-31 1 -14 -15
2017-12-31 1 -12 -14
2017-09-30 1 -10 -13
2017-06-30 1 -9 -12
2017-03-31 1 -8 -11
2016-12-31 1 -8 -10
2016-09-30 1 -8 -10
2016-06-30 1 -8 -10
2016-03-31 1 -9 -10

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Avita Medical is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Avita Medical's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:GCR Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Avita Medical Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:GCR Future Estimates Data
Date (Data in AUD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-06-30 0.00 0.00 0.00 1.00
2020-06-30 -0.01 -0.01 -0.02 2.00
2019-06-30 -0.02 -0.01 -0.02 2.00
DB:GCR Past Financials Data
Date (Data in AUD Millions) EPS *
2018-12-31 -0.02
2018-09-30 -0.02
2018-06-30 -0.02
2018-03-31 -0.02
2017-12-31 -0.02
2017-09-30 -0.02
2017-06-30 -0.02
2017-03-31 -0.02
2016-12-31 -0.02
2016-09-30 -0.02
2016-06-30 -0.02
2016-03-31 -0.02

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Avita Medical will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Avita Medical's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Avita Medical has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Avita Medical performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Avita Medical's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Avita Medical does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Avita Medical's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Avita Medical's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Avita Medical's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Avita Medical Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:GCR Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 2.86 -24.85 28.32 10.67
2018-09-30 2.25 -20.68 24.10 9.66
2018-06-30 1.65 -16.52 19.89 8.65
2018-03-31 1.37 -15.36 16.51 9.62
2017-12-31 1.27 -14.20 14.86 8.81
2017-09-30 1.22 -12.85 14.38 7.54
2017-06-30 1.18 -11.51 13.90 6.27
2017-03-31 1.07 -10.58 12.80 5.35
2016-12-31 0.95 -9.65 11.70 4.43
2016-09-30 0.98 -9.96 11.31 3.94
2016-06-30 1.00 -10.27 10.93 3.46
2016-03-31 1.04 -9.80 9.07 3.91
2015-12-31 1.07 -9.33 7.21 4.37
2015-09-30 1.03 -8.60 6.44 4.07
2015-06-30 0.99 -7.87 5.68 3.77
2015-03-31 1.39 -6.71 5.87 3.15
2014-12-31 1.80 -5.56 6.06 2.53
2014-09-30 2.24 -5.35 6.57 2.34
2014-06-30 2.68 -5.15 7.09 2.15
2014-03-31 2.76 -6.38 8.06 2.08
2013-12-31 2.83 -7.61 9.04 2.01
2013-09-30 2.82 -7.85 8.98 2.31
2013-06-30 2.81 -8.09 8.92 2.60
2013-03-31 2.90 -8.67 8.88 2.25
2012-12-31 2.99 -9.25 8.83 1.90
2012-09-30 3.17 -8.42 8.64 1.44
2012-06-30 3.35 -7.59 8.44 0.97

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Avita Medical has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Avita Medical has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Avita Medical improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Avita Medical's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Avita Medical has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Avita Medical's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Avita Medical's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Avita Medical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Avita Medical's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Avita Medical's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 421x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Avita Medical Company Filings, last reported 3 months ago.

DB:GCR Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 31.25 0.08 30.34
2018-09-30 31.25 0.08 30.34
2018-06-30 19.00 0.13 14.83
2018-03-31 19.00 0.13 14.83
2017-12-31 14.52 0.00 11.78
2017-09-30 14.52 0.00 11.78
2017-06-30 5.12 0.00 3.79
2017-03-31 5.12 0.00 3.79
2016-12-31 10.86 0.00 8.39
2016-09-30 10.86 0.00 8.39
2016-06-30 6.85 0.00 4.17
2016-03-31 6.85 0.00 4.17
2015-12-31 8.67 0.00 7.72
2015-09-30 8.67 0.00 7.72
2015-06-30 4.22 0.00 2.97
2015-03-31 4.22 0.00 2.97
2014-12-31 2.20 0.00 1.71
2014-09-30 2.20 0.00 1.71
2014-06-30 5.53 0.00 3.65
2014-03-31 5.53 0.00 3.65
2013-12-31 7.27 0.00 6.76
2013-09-30 7.27 0.00 6.76
2013-06-30 10.46 0.00 10.62
2013-03-31 10.46 0.00 10.62
2012-12-31 14.50 0.00 14.28
2012-09-30 14.50 0.00 14.28
2012-06-30 8.55 0.00 8.23
  • Avita Medical's level of debt (0.3%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 0.3% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Avita Medical has sufficient cash runway for 1.5 years based on current free cash flow.
  • Avita Medical has sufficient cash runway for 1.4 years if free cash flow continues to grow at historical rates of 33.6% each year.
X
Financial health checks
We assess Avita Medical's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Avita Medical has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Avita Medical's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Avita Medical dividends.
If you bought €2,000 of Avita Medical shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Avita Medical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Avita Medical's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:GCR Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:GCR Future Dividends Estimate Data
Date (Data in A$) Dividend per Share (annual) Avg. No. Analysts
2021-06-30
2020-06-30
2019-06-30

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Avita Medical has not reported any payouts.
  • Unable to verify if Avita Medical's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Avita Medical's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Avita Medical has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Avita Medical's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Avita Medical afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Avita Medical has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Avita Medical's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mike Perry
COMPENSATION A$1,764,038
AGE 59
TENURE AS CEO 1.8 years
CEO Bio

Dr. Michael S. Perry, also known as Mike, DVM, Ph.D., FACVPT, has been Chief Executive Officer of Avita Medical Limited since June 2, 2017 and serves as its President. Dr. Perry serves as Managing Director & Board Member at Bioscience Managers Pty Ltd. Previously, he served as Operating Partner at venture capital firm Bioscience Managers Pty Ltd. He served as a Vice President of the Integrated Hospital Care Franchise and Senior Global Program Head of Stem Cell Therapy at Novartis Pharmaceuticals Corporation sine 2012 until 2014. Dr. Perry served as the Chief Scientific Officer of Novartis’ Cell & Gene Therapy Unit from 2014 until 2017. He served as a Venture Partner at Bay City Capital LLC from 2005 to 2012. He served as President and Chief Medical Officer of Poniard Pharmaceuticals, Inc from February 5, 2010 to March 31, 2012. Dr. Perry served as the Senior Vice President and Chief Scientific Officer of Global Business Development and Licensing for Novartis AG. He served as the Chief Development Officer at VIA Pharmaceuticals Inc. from April 2005 to May 2009. He has over 25 years of successful biotechnology and pharmaceutical management experience. He was a Co-founder of Extropy Pharmaceuticals, Inc. and served as its Chairman, President and Chief Executive Officer from June 2003 to April 2005. Dr. Perry served as the President and Chief Executive Officer at Certara Strategic Consulting from February 2002 to February 10, 2003. He served as the Worldwide Head of Global R&D of Baxter's BioPharmaceuticals Business from October 2000 to 2002. From August 1998 to October 2000, he served as the President of Cell & Gene Therapy at Genetic Therapy, Inc. and served as its the President and Chief Executive Officer. From June 1997 to October 2000, he served as the President of Cell & Gene Therapy at Systemix, Inc where he also served as President and Chief Executive Officer. From 1994 to 1997, he served as the Vice President of Regulatory Affairs for Novartis Pharma. He served as the Vice President of Regulatory Affairs for Sandoz Pharma and Syntex Corporation. Dr. Perry has also held scientific and regulatory positions at Bio-Research Laboratories and Warner-Lambert/Parke Davis Research Institute. He served as a Director of Regulatory Affairs at Schering-Plough Corporation. He has a proven track record in research and development innovation with special emphasis on product development and approval, strategic portfolio management, integration of company mergers and acquisitions, business development and driving shareholder value. He has been the Chairman of Xeno Transplants Corporation since May 3, 2007. He serves as a Lead Director at Arrowhead Pharmaceuticals, Inc. He served as the Chairman of Icon Development Inc. since May 3, 2007. He has been a Non Executive Director of Avita Medical Limited since February 6, 2013; and Xeno Transplants Corporation since May 3, 2007. He has been an Independent Director of AmpliPhi Biosciences Corporation since November 2005. He has been Director at Gamida Cell Ltd. since June 2017. He serves as a Director of Navon Pharmaceuticals and a Board Observer for Itamar Medical. Dr. Perry has been an Avita non-executive director since February 2013. He has been a Director of Arrowhead Pharmaceuticals, Inc. since December 19, 2011. He has also held previous Board positions with California Healthcare Institute and Extropy Pharmaceuticals. Dr. Perry served as Novartis' observer on the Gamida Cell Board of Directors. He served as a Director of Icon Development Inc. and Arriva Pharmaceuticals, Inc. He served as a Director at Pharsight Corporation since April 2002, SyStemix Inc., Genetic Therapy Inc. and BioTransplant Incorporated since January 1999. Dr. Perry is an Adjunct Professor at the University of Colorado, School of Medicine, Gates Center for Regenerative Medicine and Stem Cell Biology and serves as Chair of the Translational Medicine Advisory Board of the Houston Methodist Research Institute. He holds a B.Sc. in Engineering and Physics, a Ph.D. in Biomedical Science with a specialization in Cardiopulmonary Pharmacology and a Doctorate in Veterinary Medicine and Surgery from the University of Guelph, Ontario, Canada. Dr. Perry is also a graduate of International Management Program at Harvard Business School.

CEO Compensation
  • Mike's compensation has increased whilst company is loss making.
  • Mike's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the Avita Medical management team in years:

1.3
Average Tenure
  • The average tenure for the Avita Medical management team is less than 2 years, this suggests a new team.
Management Team

Mike Perry

TITLE
CEO & Director
COMPENSATION
A$2M
AGE
59
TENURE
1.8 yrs

Dale Sander

TITLE
Chief Financial Officer
COMPENSATION
A$438K
AGE
58
TENURE
1.7 yrs

Tim Rooney

TITLE
Chief Administrative Officer
COMPENSATION
A$934K
TENURE
1.3 yrs

Andrew Quick

TITLE
Senior Vice President of Clinical Development
COMPENSATION
A$676K

Erin Liberto

TITLE
Chief Commercial Officer
COMPENSATION
A$738K
TENURE
1.3 yrs

Adam Kelliher

TITLE
Consultant
COMPENSATION
A$500K
TENURE
1.8 yrs

David Fencil

TITLE
Vice President of Global Operations
TENURE
3.4 yrs

Donna Shiroma

TITLE
General Counsel
TENURE
0.8 yrs

Debbie Garner

TITLE
Vice President of Global Marketing
TENURE
0.8 yrs

Mark Licciardo

TITLE
Joint Company Secretary
TENURE
1.1 yrs
Board of Directors Tenure

Average tenure and age of the Avita Medical board of directors in years:

3.3
Average Tenure
61
Average Age
  • The tenure for the Avita Medical board of directors is about average.
Board of Directors

Lou Panaccio

TITLE
Non-Executive Chairman
COMPENSATION
A$86K
AGE
61
TENURE
4.8 yrs

Mike Perry

TITLE
CEO & Director
COMPENSATION
A$2M
AGE
59
TENURE
6.2 yrs

Louis Drapeau

TITLE
Non-Executive Director
COMPENSATION
A$56K
AGE
74
TENURE
3.3 yrs

Suzanne Crowe

TITLE
Non-Executive Director
COMPENSATION
A$61K
TENURE
3.3 yrs

Fiona Wood

TITLE
Founder and Member of Clinical Advisory Board
COMPENSATION
A$40K
TENURE
3.3 yrs

Jeremy Curnock Cook

TITLE
Non-Executive Director
COMPENSATION
A$61K
AGE
68
TENURE
6.5 yrs

Damien McDonald

TITLE
Non-Executive Director
COMPENSATION
A$57K
AGE
53
TENURE
3.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
07. Apr 19 Sell Karst Peak Capital Limited Company 26. Mar 19 01. Apr 19 -20,428,231 €0.19 €-3,792,389
20. Jan 19 Buy Redmile Group, LLC Company 18. Jan 19 18. Jan 19 94,976,493 €0.05 €4,799,593
12. Dec 18 Buy Redmile Group, LLC Company 10. Dec 18 10. Dec 18 155,023,507 €0.05 €7,839,879
12. Dec 18 Buy Bioscience Managers Pty Ltd Company 27. Jul 18 27. Jul 18 1,600,000 €0.03 €50,852
06. Dec 18 Buy Karst Peak Capital Limited Company 05. Dec 18 05. Dec 18 20,669,801 €0.05 €1,059,267
20. Nov 18 Buy Karst Peak Capital Limited Company 16. Nov 18 16. Nov 18 75,317,459 €0.06 €4,685,493
28. Aug 18 Sell Deutsche Bank, Private Banking and Investment Banking Investments Company 26. Jul 18 24. Aug 18 -9,400,672 €0.06 €-592,928
28. Aug 18 Buy Deutsche Bank, Private Banking and Investment Banking Investments Company 26. Jul 18 22. Aug 18 1,732,358 €0.06 €98,567
14. Aug 18 Sell Regal Funds Management Pty Limited Company 21. Mar 18 10. Aug 18 -31,193,240 €0.04 €-1,265,453
14. Aug 18 Buy Regal Funds Management Pty Limited Company 07. Jun 18 01. Aug 18 36,220,000 €0.04 €1,305,255
27. Jul 18 Sell Deutsche Bank, Private Banking and Investment Banking Investments Company 11. Jan 18 25. Jul 18 -11,413,649 €0.05 €-579,527
27. Jul 18 Buy Deutsche Bank, Private Banking and Investment Banking Investments Company 11. Jan 18 25. Jul 18 13,431,056 €0.05 €681,960
29. Jun 18 Buy Bioscience Managers Pty Ltd Company 06. Jun 18 06. Jun 18 3,400,000 €0.03 €110,794
12. Jun 18 Buy Karst Peak Capital Limited Company 07. Jun 18 07. Jun 18 155,000,000 €0.03 €5,006,210
X
Management checks
We assess Avita Medical's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Avita Medical has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Avita Medical Limited operates as a regenerative medicine company in the Asia Pacific, Europe, the Middle East, Africa, and the Americas. It offers regenerative products for the treatment of burns, chronic wounds, and aesthetics indications. The company’s patented and proprietary collection and application technology provides treatment solutions derived from a patient’s own skin. Its lead product, RECELL System, is used in the treatment of various skin defects, such as burns and plastic reconstructive procedures. The company also offers ReGenerCell for chronic wounds and ReNovaCell for the restoration of pigmentation. Avita Medical Limited is based in Valencia, California.

Details
Name: Avita Medical Limited
GCR
Exchange: DB
Founded:
A$420,776,566
1,864,439,575
Website: http://www.avitamedical.com
Address: Avita Medical Limited
28159 Avenue Stanford,
Suite 220,
Valencia,
California, 91355,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX AVH Ordinary Shares Australian Securities Exchange AU AUD 19. Jul 1999
OTCPK AVMX.F Ordinary Shares Pink Sheets LLC US USD 19. Jul 1999
DB GCR Ordinary Shares Deutsche Boerse AG DE EUR 19. Jul 1999
BST GCR Ordinary Shares Boerse-Stuttgart DE EUR 19. Jul 1999
CHIA AVH Ordinary Shares Chi-X Australia AU AUD 19. Jul 1999
OTCPK AVMX.Y SPONSORED ADR Pink Sheets LLC US USD 09. Mar 2012
Number of employees
Current staff
Staff numbers
55
Avita Medical employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 20:46
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/05
Last earnings filing: 2019/02/27
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.